DDrare: Database of Drug Development for Rare Diseases

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Afinitor; Afinitor 5mg Tablets; Albuterol; Albuterol inhaler; Albuterol nebulizer; Bevacizumab; Celecoxib; Cetuximab; Doxycycline; Doxycycline 100 mg Capsules; EVEROLIMUS; Everolimus; Everolimus (RAD001); Everolimus Oral Product; Glutamine; Hydroxychloroquine; Imatinib; Imatinib Mesylate 400Mg Capsule; Letrozole; Nintedanib; Octreotide; Ofev; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; PFT; Procedure: PFT; RAD001; RAD001 5mg; Rapamycin; Rapamycin, sirolimus; Resveratrol; Saracatinib; Simvastatin; Sirolimus; Sirolimus Oral Product; Sirolimus and Hydroxychloroquine 200 mg; Sirolimus and Hydroxychloroquine 400 mg; Srolimus; Temsirolimus; Valproic Acid; Valproic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00989742 (ClinicalTrials.gov)	July 2009	2/10/2009	Doxycycline In Lymphangioleiomyomatosis (LAM)	A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.	Lymphangioleiomyomatosis;Tuberous Sclerosis	Drug: Doxycycline;Drug: Placebo	University of Nottingham	NULL	Completed	18 Years	N/A	Female	24	Phase 4	United Kingdom
2	EUCTR2007-003745-32-GB (EUCTR)	12/12/2008	26/11/2010	A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM	A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM	Lymphangioleiomyomatosis MedDRA version: 9.1;Level: LLT;Classification code 10049459;Term: Lymphangioleiomyomatosis MedDRA version: 9.1;Level: PT;Term: Lymphangioleiomyomatosis	Trade Name: Doxycycline 100 mg Capsules INN or Proposed INN: doxycycline	University of Nottingham	NULL	Not Recruiting			Female: yes Male: no			United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00989742
(ClinicalTrials.gov)

July 2009

2/10/2009

Doxycycline In Lymphangioleiomyomatosis (LAM)

A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.

Lymphangioleiomyomatosis;Tuberous Sclerosis

Drug: Doxycycline;Drug: Placebo

University of Nottingham

NULL

Completed

18 Years

N/A

Female

Phase 4

United Kingdom

EUCTR2007-003745-32-GB
(EUCTR)

12/12/2008

26/11/2010

A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. - Doxycycline in LAM

Lymphangioleiomyomatosis
MedDRA version: 9.1;Level: LLT;Classification code 10049459;Term: Lymphangioleiomyomatosis
MedDRA version: 9.1;Level: PT;Term: Lymphangioleiomyomatosis

Trade Name: Doxycycline 100 mg Capsules
INN or Proposed INN: doxycycline

University of Nottingham

NULL

Not Recruiting

Female: yes
Male: no

United Kingdom